Investor Area

Independent Analyst Coverage of CLINUVEL

CLINUVEL does not provide financial guidance on its earnings and financial performance. CLINUVEL does not endorse, confirm or express a view as to the accuracy of the analyst reports and the forecasts contained within them and does not make any representation that its earnings will fall within the range of the analyst’s forecasts. CLINUVEL does not induce, incentivise or remunerate analysts and journalists to publish and recommend CLINUVEL in their reports or mainstream media channels.

Firm / Institution
Analyst
Date of Publication
Analyst Profile
Firm / Institution Profile
Bioshares
David Blake & Mark Pachacz
Latest coverage: No 860, 14 September 2020

Initial coverage: No. 195, 01 December 2006

Prior to co-founding Bioshares, David Blake was a housing market analyst for the Victorian Government. He holds a Bachelor of Arts from the University of Queensland and Graduate Diplomas from the University of Melbourne and the Securities Institute of Australia. Mark Pachacz is co-founder and co-editor of Bioshares. He is a chemical engineer by training and a graduate of Monash University and the Securities Institute of Australia.
Bioshares is published by Blake Industry and Market Analysis Pty Ltd. Since 2000, Bioshares has cemented a reputation for highly knowledgeable, insightful, and independent coverage of life sciences, pharmaceutical and healthcare companies.
Intelligent Investor
Graham Witcomb
Latest coverage 28 August 2020

Initial coverage 15 June 2020

Graham Witcomb is a senior analyst focused on the healthcare, gambling, and transport infrastructure sectors. He is a graduate in psychology from the University of Sydney and a Chartered Financial Analyst charterholder.
Intelligent Investor is part of the InvestSMART Group which offers financial services to over 673,00 members through diversified and single asset class investments.
Jefferies Australia
David Stanton
Initial coverage: 13 October 2020
Dr Stanton is Head of Healthcare Equity Research Australia at Jefferies Australia Pty Ltd. He is a qualified Medical Specialist, holds a Master of Business Administration, and is an experienced and well regarded healthcare analyst. Dr Stanton has followed CLINUVEL’s development program since 2007. With Jefferies since September 2019, he has held senior analytical roles over 15 years with CSLA, Nomura, and ABN Amro.
Jefferies Financial Group Inc. (NYSE:JEF) is a leading international financial services company offering a range of investment banking, equities, fixed income, asset and wealth management products and services through subsidiaries worldwide, see https://www.jefferies.com/. Healthcare is one of the firm’s 12 focus areas, with Jefferies maintaining a dedicated global healthcare research team which issues analyst coverage on over 270 companies in the sector. The annual Jefferies Global Healthcare Conference is recognised as the largest life sciences investment event in Europe.
Lonsec Research
Chad Troja
Latest coverage: 09 September 2020

Initial coverage: 17 June 2020

Chad Troja is a senior equity analyst, experienced in portfolio management, equity markets and foreign exchange trading. He holds a Master of Applied Finance from Macquarie University and Bachelor of Business Administration from Monash University.
Lonsec Research provides investment research, portfolio consulting and managed accounts to financial advisers, fund managers, superfunds, and DIY investors.
Moelis Australia Securities
Sarah Mann
Latest coverage: 27 August 2020

Initial coverage: 17 April 2019

Sarah Mann is a prominent analyst focused on the healthcare sector. With Moelis Australia since mid-2016, Sarah was previously an analyst at Credit Suisse. She holds a Bachelor of Liberal Studies from the University of Sydney with an undergraduate thesis in Immunology. At Moelis Australia, Sarah covers a number of companies across the healthcare and consumer sectors listed on the Australian Securities Exchange (ASX).
Moelis Australia Securities Ltd is a financial services group listed on the ASX, specialising in asset management, corporate advisory, and transaction services. They have a team of over 200, research 58 ASX-listed companies, manage funds of A$4.9bn and have advised on transactions worth over A$110bn since their launch in 2009. Moelis Australia commenced as a joint venture with the New York Securities Exchange (NYSE)-listed Moelis & Company, a leading global independent investment bank and Australian executives.

Each research report is issued by a holder of an Australian Financial Services Licence. CLINUVEL does not distribute the original or copies of the analyst reports in observance of copyrights.

INDEPENDENT ANALYST COVERAGE OF CLINUVEL

CLINUVEL does not provide financial guidance on its earnings and financial performance. CLINUVEL does not endorse, confirm or express a view as to the accuracy of the analyst reports and the forecasts contained within them and does not make any representation that its earnings will fall within the range of the analyst’s forecasts. CLINUVEL does not induce, incentivise or remunerate analysts and journalists to publish and recommend CLINUVEL in their reports or mainstream media channels.

Author: Sarah Mann

Publisher: Moelis Australia Securities
Latest coverage: 27 February 2020

Initial coverage: 17 April 2019

Sarah Mann is a prominent analyst focused on the healthcare sector. With Moelis Australia since mid-2016, Sarah was previously an analyst at Credit Suisse. She holds a Bachelor of Liberal Studies from the University of Sydney with an undergraduate thesis in Immunology. At Moelis Australia, Sarah covers a number of companies across the healthcare and consumer sectors listed on the Australian Securities Exchange (ASX).
Moelis Australia Securities Ltd is a financial services group listed on the ASX, specialising in asset management, corporate advisory, and transaction services. They have a team of over 200, research 58 ASX-listed companies, manage funds of A$4.9bn and have advised on transactions worth over A$110bn since their launch in 2009. Moelis Australia commenced as a joint venture with the New York Securities Exchange (NYSE)-listed Moelis & Company, a leading global independent investment bank and Australian executives.
Author: David Blake & Mark Pachacz

Publisher: Bioshares
Latest coverage: No. 842, 11 May 2020

Initial coverage: No. 195, 01 December 2006

Prior to co-founding Bioshares, David Blake was a housing market analyst for the Victorian Government. He holds a Bachelor of Arts from the University of Queensland and Graduate Diplomas from the University of Melbourne and the Securities Institute of Australia. Mark Pachacz is co-founder and co-editor of Bioshares. He is a chemical engineer by training and a graduate of Monash University and the Securities Institute of Australia.
Bioshares is published by Blake Industry and Market Analysis Pty Ltd. Since 2000, Bioshares has cemented a reputation for highly knowledgeable, insightful, and independent coverage of life sciences, pharmaceutical and healthcare companies.
Author: Chad Troja

Publisher: Lonsec Research
Date: 17 June 2020
Chad Troja is a senior equity analyst, experienced in portfolio management, equity markets and foreign exchange trading. He holds a Master of Applied Finance from Macquarie University and Bachelor of Business Administration from Monash University.
Lonsec Research provides investment research, portfolio consulting and managed accounts to financial advisers, fund managers, superfunds, and DIY investors.
Author: Graham Witcomb

Publisher: Intelligent Investor
15 June 2020
Graham Witcomb is a senior analyst focused on the healthcare, gambling, and transport infrastructure sectors. He is a graduate in psychology from the University of Sydney and a Chartered Financial Analyst charterholder.
Intelligent Investor is part of the InvestSMART Group which offers financial services to over 673,00 members through diversified and single asset class investments.

Each research report is issued by a holder of an Australian Financial Services Licence. CLINUVEL does not distribute the original or copies of the analyst reports in observance of copyrights.